STOCK TITAN

Medicinova Inc - MNOV STOCK NEWS

Welcome to our dedicated news page for Medicinova (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medicinova's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medicinova's position in the market.

Rhea-AI Summary
MediciNova, Inc. has received a Notice of Grant from the Chinese Patent Office for a new patent covering MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than April 2040 and covers a wide range of doses, dosing frequencies, and treatment periods. The Chief Medical Officer commented on the potential of MN-166 in ophthalmic neurodegenerative diseases and the positive data from previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) announced the selection of an abstract for a poster presentation at the Society of Toxicology 63rd Annual Meeting and ToxExpo, detailing the results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury. The study will be presented by collaborator Perenlei Enkhbaatar, MD, PhD, FAHA, and funded in part by the Department of Health and Human Services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) has received a Notice of Decision to Grant from the European Patent Office for a pending patent application covering the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039 and covers a wide range of doses, dosing durations, and frequencies for the combination. The company's Chief Medical Officer believes this new patent could increase the potential value of MN-166, indicating a synergistic effect of the combination in reducing the risk of disability progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) announced positive results from a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients. The trial evaluated the combination of MN-166 and anti-PD1 or anti-PD-L1 therapy in GBM models. The primary endpoints were safety, tolerability, and efficacy. MN-166 and TMZ combination treatment was safe and well-tolerated, with a PFS6 rate of 44% for new GBM and 31% for recurrent GBM. Preclinical studies showed that adding MN-166 to anti-PD1 or anti-PD-L1 therapy significantly extended survival. Chief Medical Officer, Kazuko Matsuda, expressed excitement for the findings and future trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.73%
Tags
clinical trial
-
Rhea-AI Summary
MediciNova announces first patient treated in clinical trial for SAR444836 gene therapy for PKU
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
MediciNova receives $1 million milestone payment from Genzyme Corporation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary
MediciNova announces positive results from nonclinical studies on MN-166 as a potential treatment for chlorine gas-induced lung damage. MN-166 high dose showed a significant improvement in pulmonary function, with a 46% higher PaO2/FiO2 ratio compared to the negative control group. MN-166 has potential to treat acute lung disease from various causes. No efficacy results from the second nonclinical model study. Meeting with FDA planned for next steps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary
MediciNova, Inc. announced that an abstract on tumor tissue analysis data from a clinical trial of MN-166 in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology. The poster will be presented by Dr. Justin Lathia, and the session is scheduled for November 17, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
MediciNova, Inc. has received a Notice of Intention to Grant from the European Patent Office for a pending patent application that covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 in treating macular injury and decreasing macular volume loss associated with progressive multiple sclerosis. The patent also covers a wide range of doses and dosing frequencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
none
Medicinova Inc

Nasdaq:MNOV

MNOV Rankings

MNOV Stock Data

63.76M
42.28M
2.98%
21.16%
0.5%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
La Jolla

About MNOV

pharmaceutical preparations